INVESTIGATION THE ROLE OF GDF-15 AND ARFIP2 LEVELS IN TYPE 2 DIABETIC PATIENTS A COMPARATIVE GENDER-BASED STUDY
International Journal Multidisciplinary (IJMI) · 27.03.2026 · 3 (2) · 316-328
DOI: 10.61796/ijmi.v3i2.465 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal Multidisciplinary (IJMI), online erschienen am 27.03.2026. Verfasst von Hameedah A. Jabbar und 2 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Objective
The present study seeks to evaluate the quantification of serum levels of ADP-ribosylation factor-interacting protein 2 (ARFIP2) and growth differentiation factor-15 (GDF-15), as well as to investigate potential correlations between these factors and glycaemic control metrics and insulin resistance (HOMA-IR), in order to elucidate their roles in the pathophysiology and progression of diabetes mellitus (DM).
Method
The case-control study included 111 individuals, consisting of 51 patients diagnosed with diabetes mellitus and 60 healthy individuals serving as a control group. We measured the levels of GDF-15 and ARFIP2 in two study groups, as well as the levels of serum glycaemic markers (FBS, Insulin, HbA1c) and HOMA-IR.
Results
In T2DM, ARFIP2 showed significant correlations with FBS, insulin, and HOMA-IR suggesting its role in insulin resistance and acute glycemic regulation but showed limited associations in controls, indicating its role becomes more pronounced under diabetic conditions. GDF-15 showed a positive but non-significant correlation with ARFIP2, hinting at a possible shared pathway in metabolic stress and inflammation but in control group showed a highly significant correlation suggesting it may act as an early biomarker of metabolic stress. Novelty: ARFIP2 is strongly associated with insulin resistance and acute glycemic markers in T2DM, but not with long-term glycemic control. GDF-15 shows strong associations in controls and trends in T2DM, suggesting it may serve as an early stress-response biomarker. Gender differences in distribution were observed but not statistically significant, indicating the need for larger sample sizes to clarify gender-specific biomarker patterns.
Zitieren
APA
Jabbar, H. A., Thuwaini, M. M., & Sawafi, A. A. (2026). INVESTIGATION THE ROLE OF GDF-15 AND ARFIP2 LEVELS IN TYPE 2 DIABETIC PATIENTS A COMPARATIVE GENDER-BASED STUDY. International Journal Multidisciplinary (IJMI), 3(2), 316-328. https://doi.org/10.61796/ijmi.v3i2.465
Vancouver
Jabbar HA, Thuwaini MM, Sawafi AA. INVESTIGATION THE ROLE OF GDF-15 AND ARFIP2 LEVELS IN TYPE 2 DIABETIC PATIENTS A COMPARATIVE GENDER-BASED STUDY. International Journal Multidisciplinary (IJMI). 2026;3(2):316-328. doi:10.61796/ijmi.v3i2.465
BibTeX
@article{Jabbar2026,
author = {Jabbar, Hameedah A. and Thuwaini, Mahdi M. and Sawafi, Abeer Al},
title = {INVESTIGATION THE ROLE OF GDF-15 AND ARFIP2 LEVELS IN TYPE 2 DIABETIC PATIENTS A COMPARATIVE GENDER-BASED STUDY},
journal = {International Journal Multidisciplinary (IJMI)},
year = {2026},
volume = {3},
number = {2},
pages = {316--328},
doi = {10.61796/ijmi.v3i2.465}
}
EUVIMED